Karol Nicieja

Mr. Karol Nicieja

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Children
Verified
Journal Article
Open access
PDF file
KGKaja Giżewska-Kacprzak
Kaja Giżewska-Kacprzak
MŚMaximilian Śliwiński
Maximilian Śliwiński
KNKarol Nicieja
Karol Nicieja
LBLidia Babiak-Choroszczak
Lidia Babiak-Choroszczak
IWIreneusz Walaszek
Ireneusz Walaszek
Macrodactyly is a rare congenital limb difference manifesting as an overgrowth of one or more fingers or toes. The pathological process affects all tissues of the ray in the hand or foot. The enlargement can significantly alter the limb’s appearance and impair its function. The role of a pediatrician is to distinguish isolated macrodactyly from syndromic conditions (including PIK3CA-Related Overgrowth Spectrum) or mimicking conditions to enable early interdisciplinary consultation and treatment planning. The psychological stigma associated with this often disfiguring condition necessitates support for patients and their family. We present a practical guide for physicians who might be the first to raise suspicion of macrodactyly and initiate further diagnostics to achieve adequate treatment and support for children and caregivers.

29 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NKNatalia Kierkosz
Natalia Kierkosz
DSDominik Sobczak
Dominik Sobczak
MCMagdalena Chmielecka-Majchrzak
Magdalena Chmielecka-Majchrzak
ECEwa Czyszczoń
Ewa Czyszczoń
KNKarol Nicieja
Karol Nicieja
MCMaria Chołuj
Maria Chołuj
Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO) represent complex clinical entities characterized by a pathological shift in microbial populations within the small intestine. Despite rapidly expanding clinical research, a practical consensus regarding long-term therapeutic management remains highly fragmented. This comprehensive review evaluates the current state of international clinical guidelines concerning the three primary therapeutic pillars of SIBO: pharmacological antibiotic therapy, restrictive dietary modifications (specifically the low-FODMAP diet), and supplementation with live biotherapeutic products (probiotics). Through a systematic assessment of contemporary updates including guidelines from the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and European consensus group we analyze whether these management models should serve as concurrent, synergistic strategies or represent distinct alternative pathways. While eubiotic antibiotic interventions, predominantly utilizing rifaximin, possess the strongest evidence base for bacterial eradication, the incorporation of restrictive diets and probiotics introduces significant physiological paradoxes. This paper provides a critical clinical analysis of the interactions between these components and their quantitative impact on gut microbiome architecture. Furthermore, it outlines a synchronized, chronological management algorithm designed to minimize therapeutic conflicts, satisfy stringent peer-review requirements, and optimize sustained clinical remission.

21 June 2024 in Pomeranian Journal of Life Sciences
Verified
Journal Article
Open access
PDF file
KGKaja Giżewska-Kacprzak
Kaja Giżewska-Kacprzak
KNKarol Nicieja
Karol Nicieja
MBMonika Bracik
Monika Bracik
DSDiana Sochaczewska
Diana Sochaczewska
EBEwa Banaś
Ewa Banaś
AKAgnieszka Kordek
Agnieszka Kordek
Preterm premature rupture of membranes (pPROM) before 22–24 weeks of gestation is considered previable and poses a high risk to the chances of successful delivery. Multicystic dysplastic kidney (MCDK) is the most common form of dysplasia of this organ, usually affecting 1 kidney. A prenatal suspicion of MCDK requires escalation of the clinical process to a reference center qualified and equipped for further diagnosis and treatment. We present a unique case of prenatal pPROM at 19 weeks of gestation in a pregnancy complicated by fetal MCDK as an interesting obstetric and neonatal patient story. We have not found any published evidence on the impact of coexisting fetal congenital malformations on a pregnancy affected by previable pPROM. The aim of this study is to highlight the importance of a multidisciplinary team approach in the management of previable pPROM and the difficulties of decision-making involving both health professionals and the mother. Initially, medical management focuses on the safety of the mother, and as the fetus reaches viability, the focus shifts to the high standard of care for the child. The final successful outcome and follow-up was the effect of coordinated prenatal and postnatal medical care.